Patients with breast cancer (BC) are particularly vulnerable to the cardiotoxicity of antineoplastic treatment (hormone therapy, radiation, chemotherapy, anti-HER2 drugs) and therefore the (neo-) adjuvant treatment may have an impact on the later deterioration of cardiac function and overall performance status1,2. This evidence concerns the gene ERBB2 and breast cancer.